Literature DB >> 24810185

Artificial nutrition at the end of life: ethical issues.

Suzanne van de Vathorst1.   

Abstract

Artificial nutrition is a medical treatment that first of all needs a sound scientific base before prescribing it. This base is absent for dying patients and patients in the end stage of dementia. Because feeding is a very emotional and symbolical issue, patient and family may request this treatment despite the lack of evidence. These issues should be addressed in good communication with patient and relatives. For comatose patients and patients in a persistent vegetative state artificial nutrition is a necessary support to bridge the time until either recovery is imminent or improbable. At that moment artificial nutrition no longer contributes to the life of the patient and should be ceased. Artificial nutrition has no place in patients that voluntary decide to stop eating and drinking in order to die.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Artificial nutrition; Coma; Dementia; End-of-life issues; Ethics; PVS

Mesh:

Year:  2014        PMID: 24810185     DOI: 10.1016/j.bpg.2014.02.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  3 in total

Review 1.  Lifestyle Medicine Interventions in Patients With Advanced Disease Receiving Palliative or Hospice Care.

Authors:  Gowri Anandarajah; Haran Asher Mennillo; Gregory Rachu; Tyler Harder; Jyotsna Ghosh
Journal:  Am J Lifestyle Med       Date:  2019-02-15

Review 2.  History and Perspectives on Nutrition and Hydration at the End of Life.

Authors:  Evie G Marcolini; Andrew T Putnam; Ani Aydin
Journal:  Yale J Biol Med       Date:  2018-06-28

3.  Use of artificial nutrition near the end of life: Results from a French national population-based study of hospitalized cancer patients.

Authors:  Karine Baumstarck; Laurent Boyer; Vanessa Pauly; Veronica Orleans; Anthony Marin; Guillaume Fond; Lucas Morin; Pascal Auquier; Sébastien Salas
Journal:  Cancer Med       Date:  2019-11-26       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.